|
| | 10200HB0033ham001 | - 2 - | LRB102 04106 BMS 25297 a |
|
|
1 | | (2) limit the amount, extent, or kind of coverage |
2 | | available to the individual; or |
3 | | (3) charge the individual or a group to which the |
4 | | individual belongs a rate that is different from the rate |
5 | | charged to other individuals or groups, respectively, for |
6 | | the same coverage, unless the charge is based on sound |
7 | | underwriting or actuarial principles reasonably related to |
8 | | actual or anticipated loss experience for a particular |
9 | | risk. |
10 | | (215 ILCS 5/155.48 new) |
11 | | Sec. 155.48. Prohibited practices relating to prescription |
12 | | for or obtainment of opioid antagonist. |
13 | | (a) As used in this Section, "opioid antagonist" means any |
14 | | drug that binds to opioid receptors and blocks or otherwise |
15 | | inhibits the effects of opioids acting on those receptors to |
16 | | reverse the effects of an opioid overdose. |
17 | | (b) A company authorized to transact life insurance in |
18 | | this State may not, based solely on whether an individual has |
19 | | been prescribed or has obtained through a standing order an |
20 | | opioid antagonist: |
21 | | (1) deny coverage to the individual; |
22 | | (2) limit the amount, extent, or kind of coverage |
23 | | available to the individual; or |
24 | | (3) charge the individual or a group to which the |
25 | | individual belongs a rate that is different from the rate |